Heart failure with preserved ejection fraction in the elderly: Scope of the problem

Journal of Molecular and Cellular Cardiology

Volumn 83, Issue , 2015, Pages 73-87

  Upadhya, Bharathi ^a   Taffet, George E ^b   Cheng, Che Ping ^a   Kitzman, Dalane W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Aging; Heart failure with preserved ejection fraction; Review; Systemic disorder

Indexed keywords

ADENOVIRUS VECTOR; ALAGEBRIUM; ANTISENSE OLIGONUCLEOTIDE; CANDESARTAN; CARVEDILOL; DIGOXIN; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; IVABRADINE; MICRORNA; NEBIVOLOL; OXYGEN; PERINDOPRIL; PLACEBO; RANOLAZINE; RIOCIGUAT; SACUBITRIL PLUS VALSARTAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERELAXIN; SILDENAFIL; SITAXSENTAN; SMALL INTERFERING RNA; SPIRONOLACTONE; VALSARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

AGING; CARDIAC EQUIPMENT; CARDIAC RESYNCHRONIZATION THERAPY; CAROTID SINUS NERVE STIMULATOR; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIASTOLIC DYSFUNCTION; ELDERLY CARE; ENDURANCE TRAINING; EXERCISE; EXERCISE TOLERANCE; FRAIL ELDERLY; HEART ATRIUM SEPTUM DEFECT; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; INTERATRIAL SEPTAL DEVICE; LIVER DISEASE; MORBIDITY; MORTALITY; MUSCLE MASS; NERVE STIMULATION; NONHUMAN; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY VASCULAR DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKELETAL MUSCLE; SODIUM RESTRICTION; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME; VENTRICULAR ASSIST DEVICE; VIRAL GENE DELIVERY SYSTEM; AGED; ANIMAL; ARTERIAL STIFFNESS; DRUG EFFECTS; FEMALE; HEART STROKE VOLUME; KINESIOTHERAPY; MALE; METABOLISM; PATHOLOGY; RISK FACTOR;

AGED; AGING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ENALAPRIL; EXERCISE THERAPY; FEMALE; HEART FAILURE; HUMANS; MALE; MUSCLE, SKELETAL; RECOMBINANT PROTEINS; RELAXIN; RISK FACTORS; STROKE VOLUME; VASCULAR STIFFNESS;

EID: 84930224708     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.02.025     Document Type: Review

References (255)

1. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000, 35:1628-1637.
2. Steinberg B.A., Zhao X., Heidenreich P.A., Peterson E.D., Bhatt D.L., Cannon C.P., et al. Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes. Circulation 2012, 126:65-75.
3. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
4. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
5. Liao L., Jollis J.G., Anstrom K.J., Whellan D.J., Kitzman D.W., Aurigemma G.P., et al. Costs for Heart Failure With Normal vs Reduced Ejection Fraction. Arch Intern Med 2006, 166:112-118.
6. Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., et al. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure: A Report From the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007, 50:768-777.
7. Mohammed S.F., Borlaug B.A., Roger V.L., Mirzoyev S.A., Rodeheffer R.J., Chirinos J.A., et al. Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction/Clinical Perspective. Circ Heart Fail 2012, 5:710-719.
8. Vasan R.S., Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000, 101:2118-2121.
9. Gandhi S.K., Powers J.E., Fowle K.M., Rankin K.M., Nomeir A.M., Kitzman D.W., et al. The Pathogenesis of Acute Pulmonary Edema Associated with Hypertension. N Engl J Med 2001, 344:17-22.
10. Zile M.R., Gaasch W.H., Carroll J.D., Feldman M.D., Aurigemma G.P., Schaer G.L., et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. Circulation 2001, 104:779-782.
11. Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350:1953-1959.
12. Kawaguchi M., Hay I., Fetics B., Kass D.A. Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction. Circulation 2003, 107:714-720.
13. Mohammed S.F., Hussain S., Mirzoyev S.A., Edwards W.D., Maleszewski J.J., Redfield M.M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015, 131:550-559.
14. Kitzman D.W., Upadhya B., Vasu S. What the dead can teach the living: the systemic nature of heart failure with preserved ejection fraction. Circulation 2015, 131:522-524.
15. Burkhoff D., Maurer M.S., Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function?. Circulation 2003, 107:656-658.
16. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H. ACCF/AHA Guideline for the management of heart-failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
17. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
18. Solomon S., Zile M., Pieske B., Voors A., Shah A., Kraigher-Krainer E., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
19. Kitzman D., Upadhya B. Heart failure with preserved ejection fraction: a heterogenous disorder with multifactorial pathophysiology. J Am Coll Cardiol 2014, 63:457-459.
20. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002, 105:1387-1393.
21. Melenovsky V., Borlaug B., Rosen B., Hay I., Ferruci L., Morell C., et al. Cardiovascular Features of Heart Failure With Preserved Ejection Fraction Versus Nonfailing Hypertensive Left Ventricular Hypertrophy in the Urban Baltimore Community: The Role of Atrial Remodeling/Dysfunction. J Am Coll Cardiol 2007, 49:198-207.
22. Maurer M.S., Hummel S.L. Heart Failure With a Preserved Ejection Fraction: What Is in a Name?. J Am Coll Cardiol 2011, 58:275-277.
23. Guazzi M., Myers J., Peberdy M., Bensimhon D., Chase P., Arena R. Cardiopulmonary exercise testing variables reflect the degree of diastolic dysfunction in patients with heart failure-normal ejection fraction. J Cardiopulm Rehabil Prev 2010, 30:165-172.
24. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart Disease and Stroke Statistics -2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
25. Kitzman D.W., Gardin J.M., Gottdiener J.S., Arnold A.M., Boineau R., Aurigemma G.P., et al. Importance of heart failure with preserved systolic function in patients > or = 65 Years of Age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001, 87:413-419.
26. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Reiss C.K., Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948-1955.
27. Yancy C., Lopatin M., Stevenson L., De Marco T., Fonarow G., ADHERE Scientific Advisory Committee and Investigators Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006, 47:76-84.
28. Tribouilloy C., Rusinaru D., Mahjoub H., Soulière V., Lévy F., Peltier M., et al. Prognosis of heart failure with preserved ejection fraction: a 5year prospective population-based study. Eur Heart J 2008, 29:339-347.
29. Meta-analysis Global Group The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012, 33:1750-1757.
30. Ather S., Chan W., Bozkurt B., Aguilar D., Ramasubbu K., Zachariah A.A., et al. Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction. J Am Coll Cardiol 2012, 59:998-1005.
31. Gottdiener J., Bartz T., DeFilippi C., Kop W., Kitzman D., Barasch E., et al. Echocardiographic and biomarker phenotype of heart failure with preserved ejection fraction (HFPEF) in older individuals in comparison to hypertension without heart failure (HTN), elderly with risk factors, and healthy aging. Importance of myocyte injury, fibrosis, LV hypertrophy, and diastolic load. J Am Coll Cardiol 2012, 59:E852.
32. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011, 32:670-679.
33. Redfield M.M., Jacobsen S.J., Borlaug B.A., Rodeheffer R., Kass D.A. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005, 112:2254-2262.
34. Ferrara N., Komici K., Corbi G., Pagano G., Furgi G., Rengo C., et al. Beta-adrenergic receptor responsiveness in aging heart and clinical implications. Front Physiol 2014, 4:396.
35. Roger V. Epidemiology of heart failure. Circ Res 2013, 113:646-659.
36. Ertl G., Ruschitzka F. The Year in Cardiology 2013: heart failure. Eur Heart J 2014, 35:470-473.
37. North B., Sinclair D. The intersection between aging and cardiovascular disease. Circ Res 2012, 110:1097-1108.
38. Lakatta E. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003, 107:490-497.
39. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 2003, 107:346-354.
40. Dai D.F., Chen T., Johnson S.C., Szeto H., Rabinovitch P.S. Cardiac aging: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal 2012, 16(12):1492-1526. [Ref Type: Conference Proceeding].
41. Braunwald E. Research advances in heart failure: a compendium. Circ Res 2013, 113:633-645.
42. Spinale F., Zile M. Integrating the myocardial matrix into heart failure recognition and management. Circ Res 2013, 113:725-738.
43. Kitzman D., Brubaker P., Morgan T., Stewart K., Little W. Exercise training in older patients with heart failure and preserved ejection fraction. Circ Heart Fail 2010, 3:659-667.
44. Borlaug B., Redfield M., Melenovsky V., Kane G., Karon B., Jacobsen S., et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail 2013, 6:944-952.
45. Wohlfahrt P., Redfield M.M., Lopez-Jimenez F., Melenovsky V., Kane G.C., Rodeheffer R.J., et al. Impact of general and central adiposity on ventricular-arterial aging in women and men. JACC Heart Fail 2014, 2:489-499.
46. DeSouza C.A., Shapiro L.F., Clevenger C.M., Dinenno F.A., Monahan K.D., Tanaka H., et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000, 102:1351-1357.
47. Gerhard M., Roddy M.A., Creager S.J., Creager M.A. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996, 27:849-853.
48. Borlaug B.A., Olson T.P., Lam C.S.P., Flood K.S., Lerman A., Johnson B.D., et al. Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2010, 56:845-854.
49. Bonnema D., Webb C., Pennington W., Stroud R., Leonardi A., Clark L., et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of vetalloproteinases (TIMPs). J Card Fail 2007, 13:530-540.
50. Dobaczewski M., Chen W., Frangogiannis N. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011, 51:600-606.
51. Bujak M., Frangogiannis N. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007, 74:184-195.
52. Seeland U., Haeuseler C., Hinrichs R., Rosenkranz S., Pfitzner T., Scharffetter-Kochanek K., et al. Myocardial fibrosis in transforming growth factor-beta (1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002, 32:295-303.
53. Kuwahara F., Kai H., Tokuda K., Kai M., Takeshita A., Egashira K., et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106:130-135.
54. Brooks W., Conrad C. Myocardial fibrosis in transforming growth factor beta(1) heterozygous mice. J Mol Cell Cardiol 2000, 32:187-195.
55. Olivetti G., Giordano G., Corradi D., Melissari M., Lagrasta C., Gambert S.R., et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995, 26:1068-1079.
56. Boyle A., Shih H., Hwang J., Ye J., Lee B., Zhang Y., et al. Cardiomyopathy of aging in the mammalian heart is characterized by myocardial hypertrophy, fibrosis and a predisposition towards cardiomyocyte apoptosis and autophagy. Exp Gerontol 2011, 46:549-559.
57. Paulus W., Tschope C. A Novel Paradigm for Heart Failure with Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation. J Am Coll Cardiol 2013, 62:263-271.
58. Csiszar A., Ungvari Z., Koller A., Edwards J., Kaley G. Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol Genomics 2004, 17:21-30.
59. Csiszar A., Labinskyy N., Smith K., Rivera A., Orosz Z., Ungvari Z. Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol 2007, 170:388-398.
60. Cucoranu I., Clempus R., Dikalova A., Phelan P., Ariyan S., Dikalov S., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005, 97:900-907.
61. Dai D., Rabinovitch P. Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. Trends Cardiovasc Med 2009, 19:213-220.
62. Trifunovic A., Wredenberg A., Falkenberg M., Spelbrink J., Rovio A., Bruder C., et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429:417-423.
63. Vermulst M., Wanagat J., Kujoth G., Bielas J., Rabinovitch P., Prolla T., et al. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 2008, 40:392-394.
64. Vermulst M., Bielas J., Kujoth G., Ladiges W.C., Rabinovitch P.S., Prolla T.A., et al. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 2007, 39:540-543.
65. Taneike M., Yamaguchi O., Nakai A., Hikoso S., Takeda T., Mizote I., et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 2010, 6:600-606.
66. Terman A., Kurz T., Navratil M., Arriaga E.A., Brunk U.T. Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging. Antioxid Redox Signal 2010, 12:503-535.
67. Dai D., Johnson S., Villarin J., Chin M., Nieves-Cintron M., Chen T., et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 2011, 108:837-846.
68. Dai D., Chen T., Szeto H., Nieves-Cintron M., Kutyavin V., Santana L., et al. Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 2011, 58:73-82.
69. Mollnau H., Wendt M., Szocs K., Lasseque B., Schulz E., Oelze M., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002, 90:E58-E65.
70. Zorov D.B., Filburn C.R., Klotz L.O., Zweier J.L., Sollott S.J. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 2000, 192:1001-1014.
71. Xiao R., Tomhave E., Wang D., Ji X., Boluyt M., Cheng H., et al. Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest 1998, 101:1273-1282.
72. Lakatta E. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev 2002, 7:29-49.
73. Babusikova E., Lehotsky J., Dobrota D., Racay P., Kaplan P. Age-associated changes in Ca(2+)-ATPase and oxidative damage in sarcoplasmic reticulum of rat heart 2012, 61(5):453-460. [Ref Type: Conference Proceeding].
74. Lancel S., Qin F., Lennon S., Zhang J., Tong X., Mazzini M., et al. Oxidative posttranslational modifications mediate decreased SERCA activity and myocyte dysfunction in Galphaq-overexpressing mice. Circ Res 2010, 107:228-232.
75. Qin F., Siwik D., Lancel S., Zhang J., Kuster G., Luptak I., et al. Hydrogen peroxide-mediated SERCA cysteine 674 oxidation contributes to impaired cardiac myocyte relaxation in senescent mouse heart. J Am Heart Assoc 2013, 2:e000184.
76. Ng A., Callister R., Johnson D., Seals D. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993, 21:498-503.
77. Esler M., Turner A., Kaye D., Thompson J., Kingwell B., Morris M., et al. Aging effects on human sympathetic neuronal function. Am J Physiol 1995, 268:R278-R285.
78. Corbi G., Conti V., Russomanno G., Longobardi G., Furgi G., Filippelli A., et al. Adrenergic signaling and oxidative stress: a role for sirtuins?. Front Physiol 2013, 4:324.
79. Rinaldi B., Corbi G., Boccuti S., Filippelli W., Rengo G., Leosco D., et al. Exercise training affects age-induced changes in SOD and heat shock protein expression in rat heart. Exp Gerontol 2006, 41:764-770.
80. Corbi G., Conti V., Russomanno G., Rengo G., Vitulli P., Ciccarelli A., et al. Is physical activity able to modify oxidative damage in cardiovascular aging?. Oxid Med Cell Longev 2012, 2012. [Article ID 728547, 6 pp.].
81. Corbi G., Conti V., Scapagnini G., Filippelli A., Ferrara N. Role of sirtuins, calorie restriction and physical activity in aging. Front Biosci (Elite Ed) 2012, 4:768-778.
82. Kaye D., Esler M. Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res 2005, 66:256-264.
83. Esler M., Thompson J., Kaye D., Turner A., Jennings G., Cox H., et al. Effects of aging on the responsiveness of the human cardiac sympathetic nerves to stressors. Circulation 1995, 91:351-358.
84. Fraticelli A., Josephson R., Danziger R., Lakatta E., Spurgeon H. Morphological and contractile characteristics of rat cardiac myocytes from maturation to senescence. Am J Physiol Heart Circ Physiol 1989, 257:H259-H265.
85. Thomas S., Rich M. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Heart Fail Clin 2007, 3:381-387.
86. Li H., Ma X., Ye F., Zhang J., Zhou X., Wang Z., et al. Expressions of cardiac sympathetic norepinephrine transporter and beta1-adrenergic receptor decreased in aged rats. J Zhejiang Univ Sci B 2009, 10:203-210.
87. Dharmarajan K., Salomon S., Helmke S., Tereyua S., Rapezzi C., Falk R., et al. Genotype and phenotypic characteristics of persons with cardiac smyloidosis from the Multinational Transthyretin Amyloidosis Outcomes Survey (THAOS) Registry. J Card Fail 2011, 17:S69.
88. Bhuiyan T., Helmke S., Patel A.R., Ruberg F.L., Packman J., Cheung K., et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail 2011, 4:121-128.
89. Rapezzi C., Merlini G., Quarta C.C., Riva L., Longhi S., Leone O., et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009, 120:1203-1212.
90. Mirzoyev S.A., Edwards W.D., Mohammed S.F., Donovan J.L., Roger V.L., Grogan D.R., et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation 2010, 122.
91. Mohammed S.F., Mirzoyev S., Edwards W., Dogan A., Grogan D., Dunlay S., et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014, 2:113-122.
92. Zamore P., Haley B. Ribo-gnome: the big world of small RNAs. Science 2005, 309:1519-1524.
93. Sayed D., Hong C., Chen I., Lypowy J., Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007, 100:416-424.
94. Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013, 495:107-110.
95. Dong S., Ma W., Hao B., Hu F., Yan L., Yan X., et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 2014, 7:565-574.
96. Lam C.S., Roger V.L., Rodeheffer R.J., Bursi F., Borlaug B.A., Ommen S.R., et al. Cardiac Structure and Ventricular Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota. Circulation 2007, 115:1982-1990.
97. Borlaug B.A., Lam C.S.P., Roger V.L., Rodeheffer R.J., Redfield M.M. Contractility and Ventricular Systolic Stiffening in Hypertensive Heart Disease: Insights Into the Pathogenesis of Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2009, 54:410-418.
98. Zile M.R., Gottdiener J.S., Hetzel S.J., McMurray J.J., Komajda M., McKelvie R., et al. Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation 2011, 124:2491-2501.
99. Maurer M.S., Burkhoff D., Fried L.P., Gottdiener J., King D.L., Kitzman D.W. Ventricular Structure and Function in Hypertensive Participants With Heart Failure and a Normal Ejection Fraction: The Cardiovascular Health Study. J Am Coll Cardiol 2007, 49:972-981.
100. Solomon S.D., Verma A., Desai A., Hassanein A., Izzo J., Oparil S., et al. Effect of Intensive Versus Standard Blood Pressure Lowering on Diastolic Function in Patients With Uncontrolled Hypertension and Diastolic Dysfunction. Hypertension 2010, 55:241-248.
101. van Heerebeek L., Borbely A., Niessen H.W.M., Bronzwaer J.G.F., van der Velden J., Stienen G.J.M., et al. Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure. Circulation 2006, 113:1966-1973.
102. Su M., Lin L., Tseng Y., Chang C., Wu C., Lin J., et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 2014, 7:991-997.
103. Pitt B., Pfeffer M., Assmann S., Boineau R., Anand I., Claggett B., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014, 370:1383-1392.
104. Edelmann F., Aldo-DHF investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The aldo-dhf randomized controlled trial. JAMA 2013, 309:781-791.
105. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med 2008, 359:2456-2467.
106. Wachter R., Schmidt-Schweda S., Westermann D., Post H., Edelmann F., Kasner M., et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J 2009, 30:3027-3036.
107. Borlaug B.A., Jaber W.A., Ommen S.R., Lam C.S.P., Redfield M.M., Nishimura R.A. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011, 97:964-969.
108. Tan Y.T., Wenzelburger F., Lee E., Heatlie G., Leyva F., Patel K., et al. The Pathophysiology of Heart Failure With Normal Ejection Fraction: Exercise Echocardiography Reveals Complex Abnormalities of Both Systolic and Diastolic Ventricular Function Involving Torsion, Untwist, and Longitudinal Motion. J Am Coll Cardiol 2009, 54:36-46.
109. Phan T.T., Abozguia K., Nallur Shivu G., Mahadevan G., Ahmed I., Williams L., et al. Heart Failure With Preserved Ejection Fraction Is Characterized by Dynamic Impairment of Active Relaxation and Contraction of the Left Ventricle on Exercise and Associated With Myocardial Energy Deficiency. J Am Coll Cardiol 2009, 54:402-409.
110. Tan Y.T., Wenzelburger F., Lee E., Heatlie G., Frenneaux M., Sanderson J.E. Abnormal left ventricular function occurs on exercise in well-treated hypertensive subjects with normal resting echocardiography. Heart 2010, 96:948-955.
111. Kitzman D.W., Higginbotham M.B., Cobb F.R., Sheikh K.H., Sullivan M. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. Cardiol Board Rev 1991, 8:72-85.
112. Ohara T., Niebel C., Stewart K., Charonko J., Pu M., Vlachos P., et al. Loss of adrenergic augmentation of diastolic intra-LV pressure difference in patients with diastolic dysfunction: evaluation by color M-mode echocardiography. JACC Cardiovasc Imaging 2012, 5:861-870.
113. Weber K., Brilla C., Janicki J. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993, 27:341-348.
114. Ahmed S.H., Clark L.L., Pennington W.R., Webb C.S., Bonnema D.D., Leonardi A.H., et al. Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease. Circulation 2006, 113:2089-2096.
115. Mohammed S., Mirzoyev S., Edwards W., Dogan A., Grogan D., Dunlay S., et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014, 2:113-122.
116. Higginbotham M.B., Morris K.G., Williams R.S., McHale P.A., Coleman R.D., Cobb F.R. Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res 1986, 58:281-291.
117. Phan T., Shivu G., Weaver R., Ahmed I., Frenneaux M. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010, 3:29-34.
118. Brubaker P.H., Joo K.C., Stewart K.P., Fray B., Moore B., Kitzman D.W. Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 2006, 26:86-89.
119. Haykowsky M.J., Brubaker P.H., John J.M., Stewart K.P., Morgan T.M., Kitzman D.W. Determinants of Exercise Intolerance in Elderly Heart Failure Patients With Preserved Ejection Fraction. J Am Coll Cardiol 2011, 58:265-274.
120. Brubaker P.H., Kitzman D.W. Chronotropic Incompetence: Causes, Consequences, and Management. Circulation 2011, 123:1010-1020.
121. Cole C.R., Blackstone E.H., Pashkow F.J., Snader C.E., Lauer M.S. Heart-Rate Recovery Immediately after Exercise as a Predictor of Mortality. N Engl J Med 1999, 341:1351-1357.
122. Borlaug B.A., Nishimura R.A., Sorajja P., Lam C.S.P., Redfield M.M. Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure with Preserved Ejection Fraction. Circ Heart Fail 2010, 3:588-595.
123. Kitzman D.W., Higginbotham M.B., Cobb F.R., Sheikh K.H., Sullivan M. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991, 17:1065-1072.
124. Borlaug B.A., Melenovsky V., Russell S.D., Kessler K., Pacak K., Becker L.C., et al. Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation 2006, 114:2138-2147.
125. Ennezat P.V., Lefetz Y., Marechaux S., Six-Carpentier M., Deklunder G., Montaigne D., et al. Left Ventricular Abnormal Response During Dynamic Exercise in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction at Rest. J Card Fail 2008, 14:475-480.
126. Abudiab M.M., Redfield M.M., Melenovsky V., Olson T.P., Kass D.A., Johnson B.D., et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 2013, 15:776-785.
127. Yu C.M., Lin H., Yang H., Kong S.L., Zhang Q., Lee S.W. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002, 105:1195-1201.
128. Kraigher-Krainer E., Shah A.M., Gupta D.K., Santos A., Claggett B., Pieske B., et al. Impaired Systolic Function by Strain Imaging in Heart Failure with Preserved Ejection Fraction. J Am Coll Cardiol 2014, 63:447-456.
129. Tartiere-Kesri L., Tartiere J.M., Logeart D., Beauvais F., Cohen Solal A. Increased Proximal Arterial Stiffness and Cardiac Response With Moderate Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol 2012, 59:455-461.
130. Hundley W., Kitzman D., Morgan T., Hamilton C., Darty S., Stewart K., et al. Cardiac cycle-dependent changes in aortic area and aortic distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001, 38:796-802.
131. Kitzman D.W., Herrington D.M., Brubaker P., Moore J., Eggebeen J., Haykowsky M.J. Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension 2013, 61:112-119.
132. Puntawangkoon C., Kitzman D., Kritchevsky S., Hamilton C., Nicklas B., Leng X., et al. Reduced peripheral arterial blood flow with preserved cardiac output during submaximal bicycle exercise in elderly heart failure. J Cardiovasc Magn Reson 2009, 11:48.
133. Haykowsky M.J., Herrington D.M., Brubaker P.H., Morgan T.M., Hundley W.G., Kitzman D.W. Relationship of flow mediated arterial; dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci 2013, 68:161-167.
134. Hundley W.G., Bayram E., Hamilton C.A., Hamilton E.A., Morgan T.M., Darty S.N., et al. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. Am J Physiol Heart Circ Physiol 2007, 292:H1427-H1434.
135. Matsue Y., Suzuki M., Nagahori W., Ohno M., Matsumura A., Hashimoto Y., et al. Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 2013, 168:36-40.
136. Kitzman D.W., Nicklas B., Kraus W.E., Lyles M.F., Eggebeen J., Morgan T.M., et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 2014, 306:H1364-H1370.
137. Feihl F., Liaudet L., Waeber B., Levy B.I. Hypertension: a disease of the microcirculation?. Hypertension 2006, 48:1012-1017.
138. Boodhwani M., Sodha N.R., Mieno S., Xu S.H., Feng J., Ramlawi B., et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation 2007, 116:I31-I37.
139. Putko B.N., Wang Z., Lo J., Anderson T., Becher H., Dyck J.R., et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One 2014, 9:e99495.
140. Douglas P.S. The left atrium: a biomarker of chronicdiastolic dysfunction andcardiovascular disease risk. J Am Coll Cardiol 2003, 42:1206-1207.
141. Rossi A., Vassanelli C. Left atrium: no longer neglected. Ital Heart J 2005, 6:881-885.
142. Leung D.Y., Boyd A., Ng A.A., Chi C., Thomas L. Echocardiographic evaluation of left atrial size and function: current understanding, pathophysiologic correlates, and prognostic implications. Am Heart J 2008, 156:1056-1064.
143. Takemoto Y., Barnes M.E., Seward J.B., Lester S.J., Appleton C.A., Gersh B.J., et al. Usefulness of left atrial volume in predicting first congestive heart failure in patients>=65years of age with well-preserved left ventricular systolic function. Am J Cardiol 2005, 96:832-836.
144. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
145. Tan Y., Wenzelburger F., Lee E., Nightingale P., Heatlie G., Leyva F., et al. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. Heart 2010, 96:1017-1023.
146. Kurt M., Wang J., Torre-Amione G., Nagueh S.F. Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging 2009, 2:10-15.
147. Eicher J.C., Laurent G., Mathe A., Barthez O., Bertaux G., Philip J.L., et al. Atrial dyssynchrony syndrome: an overlooked phenomenon and a potential cause of 'diastolic' heart failure. Eur J Heart Fail 2012, 14:248-258.
148. Melenovsky V., Hwang S.J., Redfield M.M., Zakeri R., Lin G., Borlaug B.A. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 2015, [Epub ahead of print].
149. Fung J., Sanderson J., Yip G., Zhang Q., Yu C. Impact of atrial fibrillation in heart failure with normal ejection fraction: a clinical and cchocardiographic study. J Card Fail 2007, 13:649-655.
150. Zakeri R., Chamberlain A.M., Roger V.L., Redfield M.M. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013, 128:1085-1093.
151. Zakeri R., Borlaug B.A., McNulty S.E., Mohammed S.F., Lewis G.D., Semigran M.J., et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 2014, 7:123-130.
152. Lam C.S.P., Roger VrL, Rodeheffer R.J., Borlaug B.A., Enders F.T., Redfield M.M. Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Community-Based Study. J Am Coll Cardiol 2009, 53:1119-1126.
153. Guazzi M., Borlaug B. Pulmonary hypertension due to left heart disease. Circulation 2012, 126:975-990.
154. Lam C., Borlaug B., Kane G., Enders F., Rodeheffer R., Redfield M. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009, 119:2663-2670.
155. Hawkins N.M., Petrie M.C., Jhund P.S., Chalmers G.W., Dunn F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009, 11:130-139.
156. Schwartzenberg S., Redfield M.M., From A.M., Sorajja P., Nishimura R.A., Borlaug B.A. Effects of Vasodilation in Heart Failure With Preserved or Reduced Ejection Fraction: Implications of Distinct Pathophysiologies on Response to Therapy. J Am Coll Cardiol 2012, 59:442-451.
157. Melenovsky V., Hwang S., Lin G., Redfield M., Borlaug B. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014, 35:3452-3462.
158. Mohammed S.F., Hussain I., Abou Ezzeddine O.F., Takahama H., Kwon S.H., Forfia P., et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014, 130:2310-2320.
159. Schwarz K., Singh S., Dawson D., Frenneaux M. Right ventricular function in left ventricular disease: pathophysiology and implications. Heart Lung Circ 2013, 22:507-511.
160. McKie P., Schirger J., Costello-Boerrigter L., Benike S., Harstad L., Bailey K., et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol 2011, 58:2095-2103.
161. Noumi B., Teruya S., Salomon S., Helmke S., Maurer M. Blood volume measurements in patients with heart failure and a preserved ejection fraction: implications for diagnosing anemia. Congest Heart Fail 2011, 17:14-18.
162. Colombo P., Ganda A., Lin J., Onat D., Harxhi A., Iyasere J., et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012, 17:177-190.
163. Shah S. Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter. J Am Coll Cardiol 2013, 62:1339-1342.
164. Bhella P.S., Prasad A., Heinicke K., Hastings J.L., Arbab-Zadeh A., Adams-Huet B., et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail 2011, 13:1296-1304.
165. Katz S.D., Maskin C., Jondeau G., Cocke T., Berkowitz R., LeJemtel T. Near-maximal fractional oxygen extraction by active skeletal muscle in patients with chronic heart failure. J Appl Physiol 2000, 88:2138-2142.
166. Kitzman D.W., Little W.C., Brubaker P.H., Anderson R.T., Hundley W.G., Marburger C.T., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150.
167. Maeder M.T., Thompson B.R., Brunner-La Rocca H.-P., Kaye D.M. Hemodynamic Basis of Exercise Limitation in Patients With Heart Failure and Normal Ejection Fraction. J Am Coll Cardiol 2010, 56:855-863.
168. Haykowsky M., Brubaker P., Kitzman D. Role of Physical Training in Heart Failure with Preserved Ejection Fraction. Curr Heart Fail Rep 2012, 9:101-106.
169. Haykowsky M.J., Brubaker P.H., Stewart K.P., Morgan T.M., Eggebeen J., Kitzman D.W. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol 2012, 60:120-128.
170. Pandey A., Parashar A., Kumbhani D.J., Agarwal S., Garg J., Kitzman D., et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail 2015, 8:33-40.
171. Buford T.W., Lott D.J., Marzetti E., Wohlgemuth S.E., Vandenborne K., Pahor M., et al. Age-related differences in lower extremity tissue compartments and associations with physical function in older adults. Exp Gerontol 2012, 47:38-44.
172. Franssen F., Wouters E., Schols A. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 2002, 21:1-14.
173. Coats A., Clark A., Piepoli M., Volterrani M., Poole-Wilson P. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 1994, 72:S39.
174. Middlekauff H.R. Making the Case for Skeletal Myopathy as the Major Limitation of Exercise Capacity in Heart Failure. Circ Heart Fail 2010, 3:537-546.
175. Beavers K., Beavers D., Houston D., Harris T., Hue T., Koster A., et al. Associations between body composition and gait-speed decline: results from the Health, Aging, and Body Composition study. Am J Clin Nutr 2013, 97:552-560.
176. von Haehling S., Horwich T.B., Fonarow G.C., Anker S.D. Tipping the Scale: Heart Failure, Body Mass Index, and Prognosis. Circulation 2007, 116:588-590.
177. Harrington D., Anker S.D., Chua T.P., Webb-Peploe K.M., Ponikowski P.P., Poole-Wilson P.A., et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997, 30:1758-1764.
178. Anker S.D., Ponikowski P., Varney S., Chua T.P., Clark A.L., Webb-Peploe K.M., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050-1053.
179. Fielding R.A., Vellas B., Evans W.J., Bhasin S., Morley J.E., Newman A.B., et al. Sarcopenia: an undiagnosed condition in older adults. Current donsensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 2011, 12:249-256.
180. Fried L.P., Hadley E.C., Walston J.D., Newman A.B., Guralnik J.M., Studenski S., et al. From bedside to bench: research agenda for frailty. Sci Aging Knowledge Environ 2005, 2005:pe24.
181. Haykowsky M., Brubaker P., Morgan T., Kritchevsky S., Eggebeen J., Kitzman D. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J Gerontol A Biol Sci Med Sci 2013, 68:968-975.
182. Haykowsky M., Kouba E.J., Brubaker P.H., Nicklas B.J., Eggebeen J., Kitzman D.W. Skeletal muscle composition and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol 2014, 113:1211-1216.
183. Heinonen I., Bucci M., Kemppainen J., Knuuti J., Nuutila P., Boushel R., et al. Regulation of subcutaneous adipose tissue blood flow during exercise in humans. J Appl Physiol 2012, 112:1059-1063.
184. Civitarese A.E., Carling S., Heilbronn L.K., Hulver M.H., Ukropcova B., Deutsch W.A., et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 2007, 4:e76.
185. Rossiter H.B. Exercise: Kinetic Considerations for Gas Exchange. Comprehensive Physiology 2010, John Wiley & Sons, Inc.
186. Poole D.C., Hirai D.M., Copp S.W., Musch T.I. Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance. Am J Physiol Heart Circ Physiol 2012, 302:H1050-H1063.
187. Stuart C.A., McCurry M.P., Marino A., South M.A., Howell M.E.A., Layne A.S., et al. Slow-Twitch Fiber Proportion in Skeletal Muscle Correlates With Insulin Responsiveness. J Clin Endocrinol Metab 2013, 98:2027-2036.
188. Sullivan M.J., Green H.J., Cobb F.R. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990, 81:518-527.
189. Sullivan M.J., Green H.J., Cobb F.R. Altered skeletal muscle metabolic response to exercise in chronic heart failure. Relation to skeletal muscle aerobic enzyme activity. Circulation 1991, 84:1597-1607.
190. Sullivan M.J., Duscha B.D., Klitgaard H., Kraus W.E., Cobb F., Saltin B. Altered expression of myosin heavy chain in human skeletal muscle in chronic heart failure. Med Sci Sports Exerc 1997, 29.
191. Toth M., Matthews D.E., Ades P.A., Tischler M.D., Van Buren P., Previs M., et al. Skeletal muscle myofibrillar protein metabolism in heart failure: relationship to immune activation and functional capacity. Am J Physiol Endocrinol Metab 2005, 288:E685-E692.
192. Larsson L., Sjodin B., Karlsson J. Histochemical and biochemical changes in human skeletal muscle with age in sedentary males, age 22-65 years. Acta Physiol Scand 1978, 103:31-39.
193. Coggan A.R., Spina R.J., King D.S. Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men and women. J Gerontol 1992, 47:B71-B76.
194. Kitzman D.W., Hundley W.G., Brubaker P., Stewart K., Little W.C. A randomized, controlled, double-blinded trial of enalapril in older patients with heart failure and preserved ejection fraction; effects on exercise tolerance, and arterial distensibility. Circ Heart Fail 2010, 3:477-485.
195. Matsubara J., Sugiyama S., Nozaki T., Sugamura K., Konishi M., Ohba K., et al. Pentraxin 3 Is a New Inflammatory Marker Correlated With Left Ventricular Diastolic Dysfunction and Heart Failure With Normal Ejection Fraction. J Am Coll Cardiol 2011, 57:861-869.
196. Kalogeropoulos A., Georgiopoulou V., Psaty B., Rodondi N., Smith A., Harrison D., et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010, 55:2129-2137.
197. Collier P., Watson C., Voon V., Phelan D., Jan A., Mak G., et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. Eur J Heart Fail 2011, 13:1087-1095.
198. Shah K., Kop W., Christenson R., Diercks D., Henderson S., Hanson K., et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 2011, 57:874-882.
199. Franceschi C., Bonafe M., Valensin S., Olivieri F., De Luca M., Ottaviani E., et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:244-254.
200. Packer M. Can Brain Natriuretic Peptide Be Used to Guide the Management of Patients With Heart Failure and a Preserved Ejection Fraction?: The Wrong Way to Identify New Treatments for a Nonexistent Disease. Circ Heart Fail 2011, 4:538-540.
201. Campbell R.T., Jhund P.S., Castagno D., Hawkins N.M., Petrie M.C., McMurray J.J.V. What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?. J Am Coll Cardiol 2012, 60:2349-2356.
202. Chaudhry S.I., McAvay G., Chen S., Whitson H., Newman A.B., Krumholz H.M., et al. Risk Factors for Hospital Admission Among Older Persons With Newly Diagnosed Heart FailureFindings From the Cardiovascular Health Study. J Am Coll Cardiol 2013, 61:635-642.
203. Lupon J., Gonzalez B., Santaeugenia S., Altimir S., Urrutia A., Mas D., et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. Rev Esp Cardiol 2008, 61:835-842.
204. Duscha B.D., Annex B.H., Green H.J., Pippen A.M., Kraus W.E. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll Cardiol 2002, 39:1170-1174.
205. Simonini A., Long C.S., Dudley G.A., Yue P., McElhinny J., Massie B.M. Heart Failure in Rats Causes Changes in Skeletal Muscle Morphology and Gene Expression That Are Not Explained by Reduced Activity. Circ Res 1996, 79:128-136.
206. Groban L., Pailes N.A., Bennett C., Carter C.S., Chappell M.C., Kitzman D.W., et al. Growth Hormone Replacement Attenuates Diastolic Dysfunction and Cardiac Angiotensin II Expression in Senescent Rats. J Gerontol A Biol Sci Med Sci 2006, 61:28-35.
207. Groban L., Yamaleyeva L.M., Westwood B.M., Houle T.T., Lin M., Kitzman D.W., et al. Progressive diastolic dysfunction in the female mRen(2). Lewis Rat: Influence of salt and ovarian hormones. Gerontol B Physiol Sci Soc Sci 2008, 63:3-11.
208. Lasocki S., Iglarz M., Seince P.F., Vuillaumier-Barrot S., Vicaut E., Henrion D., et al. Involvement of renin-angiotensin system in pressure-flow relationship: role of angiotensin-converting enzyme gene polymorphism. Anesthesiology 2002, 96:271-275.
209. Little W.C., Wesley-Farrington D.J., Hoyle J., Brucks S., Robertson S., Kitzman D.W., et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. J Cardiovasc Pharmacol 2004, 43:288-293.
210. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
211. Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
212. Deswal A., Richardson P., Bozkurt B., Mann D. Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). J Card Fail 2011, 17:634-642.
213. Patel K., Fonarow G.C., Kitzman D.W., Aban I.B., Love T.E., Allman R.M., et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail 2013, 1:40-47.
214. Pfeffer M.A., Claggett B., Assmann S.F., Boineau R., Anand I.S., Clausell N., et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015, 131:34-42.
215. Yamamoto K., Origasa H., Hori M. J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013, 1:110-118.
216. Conraads V., Metra M., Kamp O., De Keulenaer G., Pieske B., Zamorano J., et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012, 14:219-225.
217. Hernandez A.F., Hammill B.G., O'Connor C.M., Schulman K.A., Curtis L.H., Fonarow G.C. Clinical Effectiveness of Beta-Blockers in Heart Failure: Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry. J Am Coll Cardiol 2009, 53:184-192.
218. Ahmed A., Rich M.W., Fleg J.L., Zile M.R., Young J.B., Kitzman D.W., et al. Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial. Circulation 2006, 114:397-403.
219. Holland D.J., Kumbhani D.J., Ahmed S.H., Marwick T.H. Effects of Treatment on Exercise Tolerance, Cardiac Function, and Mortality in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis. J Am Coll Cardiol 2011, 57:1676-1686.
220. Redfield M., Chen H., Borlaug B., Semigran M., Lee K., Lewis G., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2013, 309:1268-1277.
221. Bonderman D., Pretsch I., Steringer-Mascherbauer R., Jansa P., Rosenkranz S., Tufaro C., et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (dilate-1): A randomized, double-blind, placebo-controlled, single-dose study. Chest J 2014, 146:1274-1285.
222. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Tsutsui H., et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004, 109:2234-2239.
223. Martin J., Denver R., Bailey M., Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 2005, 32:697-701.
224. Fukuta H., Sane D.C., Brucks S., Little W.C. Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary Report. Circulation 2005, 112:357-363.
225. Fukuta H., Little W. Observational studies of statins in heart failure with preserved systolic function. Heart Fail Clin 2008, 4:209-216.
226. Kosmala W., Holland D.J., Rojek A., Wright L., Przewlocka-Kosmala M., Marwick T.H. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 2013, 62:1330-1338.
227. Maurer M.S., Teruya S., Chakraborty B., Helmke S., Mancini D. Treating Anemia in Older Adults with Heart Failure with a Preserved Ejection Fraction (HFPEF) with Epoetin Alfa: Single Blind Randomized Clinical Trial of Safety and Efficacy. Circ Heart Fail 2013, 6:254-263.
228. Little W.C., Zile M.R., Kitzman D.W., Hundley W.G., O'Brien T.X., deGroof R.C. The Effect of Alagebrium Chloride (ALT-711), a Novel Glucose Cross-Link Breaker, in the Treatment of Elderly Patients with Diastolic Heart Failure. J Card Fail 2005, 11:191-195.
229. Jacobshagen C., Belardinelli L., Hasenfuss G., Maier L. Ranolazine for the Treatment of Heart Failure With Preserved Ejection Fraction: Background, Aims, and Design of the RALI-DHF Study. Clin Cardiol 2011, 34:426-432.
230. Maier L.S., Layug B., Karwatowska-Prokopczuk E., Belardinelli L., Lee S., Sander J., et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 2013, 1:115-122.
231. Teerlink J.R., Cotter G., Davison B.A., Felker G.M., Filippatos G., Greenberg B.H., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2012, 381:29-39.
232. Metra M., Cotter G., Davison B.A., Felker G.M., Filippatos G., Greenberg B.H., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013, 61:196-206.
233. Filippatos G., Teerlink J.R., Farmakis D., Cotter G., Davison B.A., Felker G.M., et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2014, 35:1041-1050.
234. Zile M.R., Bourge R.C., Redfield M.M., Zhou D., Baicu C.F., Little W.C. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail 2014, 2:123-130.
235. Jessup M., Greenberg B., Mancini D., Cappola T., Pauly D., Jaski B., et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011, 124:304-313.
236. Zsebo K., Yaroshinsky A., Rudy J.J., Wagner K., Greenberg B., Jessup M., et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014, 114:101-108.
237. Bartolini M., Andrisano V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem 2010, 11:1018-1035.
238. Falk R., Maurer M., Fedson S., Judge D., Zeldenrust S., Quyyumi A., et al. Tafamidis stabilizes transthyretin and improves clinical outcomes in transthyretin amyloid cardiomyopathy. J Card Fail 2011, 17:S56.
239. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
240. Benson M.D., Kluve-Beckerman B., Zeldenrust S.R., Siesky A.M., Bodenmiller D.M., Showalter A.D., et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006, 33:609-618.
241. Kitzman D.W., Upadhya B., Reeves G. Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient. JACC Heart Fail 2015, [in press].
242. Edelmann F., Gelbrich G., Dungen H., Frohling S., Wachter R., Stahrenberg R., et al. Exercise Training Improves Exercise Capacity and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction: Results of the Ex-DHF (Exercise training in Diastolic Heart Failure) Pilot Study. J Am Coll Cardiol 2011, 58:1780-1791.
243. Kitzman D., Brubaker P., Herrington D., Morgan T., Stewart K., Hundley W., et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: A randomized, controlled, single-blind trial. J Am Coll Cardiol 2013, 62:584-592.
244. Rickard A., Morgan J., Tesch G., Funder J., Fuller P., Young M. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood Pressure. Hypertension 2009, 54:537-543.
245. Klotz S., Hay I., Zhang G., Maurer M., Wang J., Burkhoff D. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension 2006, 47:901-911.
246. Matsui H., Ando K., Kawarazaki H., Nagae A., Fujita M., Shimosawa T., et al. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 2008, 52:287-294.
247. Hummel S., Seymour E., Brook R., Kolias T., Sheth S., Rosenblum H., et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 2012, 60:1200-1206.
248. Hummel S., Seymour E., Brook R., Sheth S., Ghosh E., Zhu S., et al. Low-sodium DASH diet Improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail 2013, 6:1165-1171.
249. Kaye D., Shah S.J., Borlaug B.A., Gustafsson F., Komtebedde J., Kubo S., et al. Effects of an interatrial shunt on rest and exercise hemodynamics: results of a computer simulation in heart failure. J Card Fail 2014, 20:212-221.
250. Sondergaard L., Reddy V., Kaye D., Malek F., Walton A., Mates M., et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 2014, 16:796-801.
251. Georgakopoulos D., Little W.C., Abraham W.T., Weaver F.A., Zile M.R. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail 2011, 17:167-178.
252. Abraham W.T., Adamson P.B., Bourge R.C., Aaron M.F., Costanzo M.R., Stevenson L.W., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 1919, 377:658-666.
253. Adamson P.B., Abraham W.T., Bourge R.C., Costanzo M.R., Hasan A., Yadav C., et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014, 7:935-944.
254. Meyns B., Klotz S., Simon A., Droogne W., Rega F., Griffith B., et al. Proof of concept: hemodynamic response to long-term partial ventricular support with the synergy pocket micro-pump. J Am Coll Cardiol 2009, 54:79-86.
255. Penicka M., Kocka V., Herman D., Trakalova H., Herold M. Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressure-volume loop analysis. Eur J Heart Fail 2010, 12:634-636.